Efficacy of the GMALL ‐B‐ALL/NHL2002 Protocol in Burkitt Leukaemia/Lymphoma and Aggressive Non‐Hodgkin‐Lymphomas with or without CNS‐Involvement
ConclusionThis study confirmed the activity of the GMALL ‐B‐ALL/NHL2002 protocol in BL/B‐LBL. It was also effective in first‐line treated non‐BL/B‐LBL lymphomas with and without simultaneous CNS‐/peripheral involvement, but ineffective in relapsed/refractory disease.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Maria Sakarou,
Lewin Eisele,
Ulrich D ührsen,
Andreas Hüttmann Tags: Original Article Source Type: research
More News: Burkitt Lymphoma | Chemotherapy | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Study | Toxicology